

(Biphenyl-4-yl)methylammonium Chlorides: Potent Anticonvulsants That Modulate Na⁺ Currents


Hyosung Lee,^{†,¶} Ki Duk Park,^{†,¶} Xiao-Fang Yang,[‡] Erik T. Dustrude,^{||} Sarah M. Wilson,^{||} Rajesh Khanna,^{‡,§,||} and Harold Kohn^{*,†,⊥}

[†]Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy and [⊥]Department of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599, United States



[‡]Department of Pharmacology and Toxicology, [§]Department of Biochemistry and Molecular Biology, and ^{||}Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202, United States

S Supporting Information

ABSTRACT: We have reported that compounds containing a biaryl linked unit (Ar-X-Ar') modulated Na⁺ currents by promoting slow inactivation and fast inactivation processes and by inducing frequency (use)-dependent inhibition of Na⁺ currents. These electrophysiological properties have been associated with the mode of action of several antiepileptic drugs. In this study, we demonstrate that the readily accessible (biphenyl-4-yl)methylammonium chlorides (compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the maximal electroshock seizure test the activity of (3'-trifluoromethoxybiphenyl-4-yl)-methylammonium chloride (**8**) exceeded that of phenobarbital and phenytoin upon oral administration to rats. Electrophysiological studies of **8** using mouse catecholamine A-differentiated cells and rat embryonic cortical neurons confirmed that **8** promoted slow and fast inactivation in both cell types but did not affect the frequency (use)-dependent block of Na⁺ currents.



Lacosamide¹ (**1**) is a first-in-class antiepileptic drug (AED) that has been introduced in 34 countries, including the U.S., as an adjunctive therapy for the treatment of partial-onset seizures.² Whole-cell, patch-clamp electrophysiology showed that **1** reduced Na⁺ channel availability by a mechanism consistent with its increasing the transition of Na⁺ channels to the slow-inactivated state without affecting the fast inactivation process.^{3–5} (For an alternative mechanism where the agent blocks Na⁺ channel fast-inactivated channels with very slow kinetics, see ref 6). We demonstrated that lacosamide analogues in which the *N*-benzyl amide group was extended by an additional aryl unit to give compound class A exhibited pronounced anticonvulsant activity in proven rodent seizure models.⁷ Electrophysiological examination of A in neuronal-like catecholamine A-differentiated (CAD) cells showed that these compounds promoted Na⁺ channel slow inactivation and that several compounds were 40–80-fold more potent than **1**.⁸ Interestingly, we found that members of compound class A, unlike **1**, affected Na⁺ channel fast inactivation and exhibited frequency (use)-dependent inhibition of Na⁺ channel firing. We investigated the origin of A's increased potency, compared to that of **1**, for Na⁺ channel slow inactivation and showed that both the core "lacosamide unit" and the "biaryl linked unit" (Figure 1) promoted slow inactivation.⁹



In this study, we asked if compounds conforming to the biaryl linked unit exhibited anticonvulsant activity in rodents. Here, we focus on substituted (biphenyl-4-yl)-methylammonium chlorides (**B**) wherein the aryl linker (X) is a single bond. We report that compound class B showed a broad profile of anticonvulsant activity, and when a selected compound of class B was given orally to rats, potent activity in the maximal electroshock seizure¹⁰ (MES) model that was comparable to the clinical agents phenobarbital and phenytoin was seen.¹¹

RESULTS AND DISCUSSION

Choice of Compounds. We selected 10 (biphenyl-4-yl)methylammonium chlorides (**B**) in which the substituent

Received: May 12, 2013

Published: June 17, 2013





Figure 1. Key structural units in compound class A that affect Na⁺ channel slow inactivation.



(Y) and the site of substitution on the terminal aryl unit were varied (Table 1, compounds 2–11). Both electron-withdrawing and electron-donating substituents were chosen. In most instances, the groups were placed at either the 3' (5, 7, 8, 12, 13) or the 4' (6, 8, 11) position since earlier structure–activity relationship studies on **1**¹² and compound class A⁷ derivatives showed substitution at these sites provided compounds with excellent anticonvulsant activities. In the case of the trifluoromethoxy (CF₃O) substituent, we prepared the 2', 3', and 4' regioisomers (9–11). The compounds were purified and tested as their hydrochloride salts.

Chemistry. The (biphenyl-4-yl)methylammonium chlorides 3–11 were prepared using Suzuki coupling¹³ of 4-bromobenzyl amine (**12**) with the appropriate, commercially available substituted phenylboronic acids (**13**–**21**) to give the amines, which then were immediately converted to their hydrochloride salts 3–11 (Scheme 1). For hydrochloride salt **2**, we treated a commercial sample of 4-(phenyl)benzylamine with HCl in dioxane.

Pharmacological Activity. Compounds 2–11 were tested for anticonvulsant activity at the Anticonvulsant Screening Program (ASP) of the National Institute of Neurological Disorders and Stroke (NINDS) at the U.S. National Institutes of Health. Screening was performed using the procedures described by Stables and Kupferberg.¹⁴ The anticonvulsant activity data from the MES,¹⁰ psychomotor 6 Hz,¹⁵ and scMetrazol¹⁶ (scMet) tests are summarized in Table 1, along with similar results obtained for **1** and the clinical AEDs phenytoin,¹¹ valproate,¹¹ and phenobarbital.¹¹ All compounds were administered intraperitoneally (ip) to mice and ip or orally (po) to rats. For compounds that showed significant activity, we report the 50% effective dose (ED₅₀) values obtained in quantitative screening evaluations. We also provide the median doses for 50% neurological impairment (TD₅₀) in mice (rotorod test¹⁷) and in rats¹⁸ (behavioral toxicity effects).

Compounds **5** and **8** displayed activities (50–100 mg/kg) in mice (ip) in the three seizure models (MES, 6 Hz, scMet), whereas **2**, **3**, **4**, **7**, **9**, and **10** displayed activities (30–100 mg/kg) in two of the three assays. The observed seizure protection of **3**, **5**, and **8** in the scMet model was interesting since **1**¹² and compounds belonging to class A⁷ did not display anticonvulsant activity in this model. The broad whole-animal pharmacological profile for several Bs suggested that these compounds exert their anticonvulsant activities through multiple pathways. For the trifluoromethoxy-substituted compounds 7–9, we found that the 3'-trifluoromethoxy derivative **8** was the most potent in the MES test (mice, ip). Finally, for 2–11, we did not observe a clear trend on the effect


of the electronic properties of the terminal aryl substituent (Y) on anticonvulsant activity.

In mice (ip), **8** was among the most active (biphenyl-4-yl)methylammonium chlorides. We observed ED₅₀ values of 25 mg/kg, 43 mg/kg, and 81 mg/kg in the MES, 6 Hz, and scMet seizure models, respectively. When **8** was tested in the MES model in rats (po), the ED₅₀ value was 8.7 mg/kg. Compound **8** showed no neurotoxicity in rats (po) at doses as high as 500 mg/kg, providing a protective index (PI = TD₅₀/ED₅₀) of >57. The oral activity of **8** exceeded that of phenytoin,¹¹ phenobarbital,¹¹ and valproate¹¹ and was approximately 2-fold less active than **1**.¹ Similar activity for **8** was observed in the rat after ip administration (MES ED₅₀ = 16 mg/kg; TD₅₀ = 72 mg/kg). When tested in the iv Metrazol test¹⁸ (mice, ip) at 25 mg/kg and 81 mg/kg there was no statistical difference from the control group in seizure threshold.

The excellent activity observed for **8** led us to examine its cellular activity by patch-clamp electrophysiology using CAD cells. We have previously shown that CAD cells express endogenous tetrodotoxin-sensitive Na⁺ currents with rapid activation and inactivation kinetics upon membrane depolarization and are likely mediated by Na_v1.7, Na_v1.1, and Na_v1.3 channels.^{5,9} Moreover, we found that the Na⁺ channel properties of **1** in CAD cells⁵ were similar to those reported in cultured neurons and mouse N1E-115 neuroblastoma cells.³ Accordingly, we used readily accessible CAD cells to evaluate the effect of **8** on neuronal function, recognizing in advance that CAD cells do not express the same complement of Na⁺ channels expressed in central nervous system (CNS) neurons. We found that **8** preferentially promoted Na⁺ channel slow inactivation (Figure 2A–D). The Na⁺ slow inactivation IC₅₀ value at –50 mV was 2.7 μM, which was approximately 30 times more potent than **1** (IC₅₀ = 85 μM).⁵ We chose the potential of –50 mV for three reasons: (1) a large fraction of the channels undergo steady-state inactivation, which involves contributions from slow and fast inactivation pathways,^{19,20} where –50 mV is within the steep voltage-dependence range for each; (2) it is near the resting membrane potential and approaches the action potential firing threshold for CNS neurons,²¹ where slow inactivation appears to be physiologically relevant during sustained subthreshold depolarizations;²² and (3) changes in the Na⁺ channel availability near –50 mV can impact the overlap of Na⁺ current activating and inactivating under steady-state conditions.^{19,23}

We found that **8** did not affect Na⁺ channel steady-state activation, defined as the relationship between voltage and a shift of channels from closed to open conformations, but did modify steady-state fast inactivation, defined as the relationship between voltage and a shift of channel gating from open to inactivated conformations over several hundred milliseconds (Figure 3). Steady-state fast inactivation was assessed using a previously described protocol designed to induce a fast-inactivated state.^{5,8,9} Cells were held at –80 mV, stepped to

Table 1. Anticonvulsant Activities of (Biphenyl-4-yl)methylammonium Chlorides (B)^a

Cmpd No.		mice (ip) ^b [hour]				rat ^c [hour]			
		MES ^d	6 Hz ^e	scMet ^f	Tox ^g	ip		oral	
						MES ^d	Tox ^h	MES ^d	Tox ^h
2	Y = H	30~100 [0.25-0.5]	~100 [0.5-1.0]	>300 [0.5-4.0]	>100 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
3	Y = 3'-F	>50 [0.25-4.0]	~50 [1.0]	~50 [2.0]	>100 [0.25-4.0]	~65 [0.25]	>65 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
4	Y = 4'-F	~50 [4.0]	<100 [1.0-4.0]	>50 [0.25-4.0]	>50 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
5	Y = 3'-Cl	<100 [0.25, 1.0]	<100 [0.5-4.0]	<100 [0.5-2.0]	>100 [0.25-4.0]	~65 [0.25-0.5]	~65 [0.25-0.5]	>30 [0.25-4.0]	>30 [0.25-4.0]
6	Y = 4'-Cl	>50 [0.25-4.0]	<100 [1.0-4.0]	>50 [0.25-4.0]	>50 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
7	Y = 2'-OCF ₃	40 [0.25] (28-59)	<50 [0.25-1.0]	>120 [0.25]	72 [0.25] (59-84)	<30 [0.25-2.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
8	Y = 3'-OCF ₃	25 [0.5] (20-34)	43 [1.0] (35-53)	81 [4.0] (60-118)	81 [6.0] (58-99)	16 [2.0] (15-18)	72 [2.0] (46-79)	8.7 [2.0] (5.1-13.3)	>500 [0.25-24.0]
9	Y = 4'-OCF ₃	~50 [0.5-2.0]	<100 [2.0]	>50 [0.25-4.0]	>50 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
10	Y = 3'-OCH ₃	<100 [0.25]	~100 [1.0]	>100 [0.5-4.0]	>100 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
11	Y = 3'-C(O)OCH ₃	~100 [0.5]	>300 [0.5-2.0]	ND ⁱ	100-300 [0.5-2.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]	>30 [0.25-4.0]
	lacosamide ^j (1)	4.5 [0.5] (3.7-5.5)			27 [0.25] (26-28)			3.9 [2.0] (2.9-6.2)	>500
	phenytoin ^k	9.5 [2.0] (8.1-10)			66 [2.0] (53-72)			30 [40] (22-39)	
	phenobarbital ^k	22 [1.0] (15-23)			69 [0.5] (63-73)			9.1 [5.0] (7.6-12)	61 [0.5] (44-96)
	valproate ^k	270 [0.25] (250-340)			430 [0.25] (370-450)			490 [0.5] (350-730)	280 [0.5] (190-350)

^aThe compounds were tested through the auspices of the NINDS ASP. ^bThe compounds were administered intraperitoneally (ip) to mice. ED₅₀ and TD₅₀ values are in milligrams per kilogram. Numbers in parentheses are 95% confidence intervals. A dose–response curve was generated for all compounds that displayed sufficient activity. The dose–effect data for these compounds was obtained at the “time of peak effect” (indicated in hours in the brackets). ^cThe compounds were administered either ip or orally (po) to rats. ^dMES = maximal electroshock seizure test. ^e6 Hz = 6 Hz psychomotor seizure test (32 mA). ^fscMet = subcutaneous pentylenetetrazol test. ^gTox = rotorod test. ^hTox = behavioral toxicity. ⁱND = not determined. ^jReference 1. ^kReference 11.

inactivating prepulse potentials ranging from −120 to −10 mV (in 10-mV increments) for 500 ms, and then stepped to 0 mV for 20 ms to measure the available current (Figure 3, top left protocol). A 500-ms conditioning pulse was used because it allowed all of the endogenous channels to transition to a fast-inactivated state at all potentials examined. Steady-state, fast inactivation curves of Na⁺ currents from DMSO-treated and various concentrations of **8**-treated CAD cells were well fitted with a single Boltzmann function ($R^2 > 0.935$ for all conditions) and are illustrated in Figure 3 (leftmost curves). The $V_{1/2}$ value for inactivation of 0.1% DMSO-treated cells was -71.6 ± 0.6

mV ($n = 6$), which was significantly different from the $V_{1/2}$ values of all concentrations of **8**-treated CAD cells ($p > 0.05$; ANOVA with a posthoc Dunnett's test). The 1 μ M concentration of **8** caused a significant hyperpolarizing shift of ~ 11.2 mV, while the 30 μ M concentration of **8** caused a significant hyperpolarizing shift of ~ 26.5 mV with no commensurate significant changes in slope values compared with control cells. The slopes of fast inactivation were not affected by **8**. Steady-state activation, as measured by 15 ms depolarizing pulses from −70 to +80 mV (in 10-mV increments) produced equivalent $V_{1/2}$ and slope values in all

Scheme 1. Synthesis of (Biphenyl-4-yl)methylammonium Chlorides (B)






Figure 2. Effect on steady-state slow inactivation state of Na^+ currents in mouse CAD cells by **8**. (A) Currents were evoked by 5 s prepulses between -120 and -20 mV, and then fast-inactivated channels were allowed to recover for 150 ms at a hyperpolarized pulse to -120 mV. The fraction of channels available at 0 mV was analyzed. (B) Representative current traces from CAD cells in the absence (control, 0.1% DMSO) or presence of 1 μM of **8** as indicated. The blue (control) and red (**8**) traces represent the current at -50 mV. (C) Summary of steady-state slow activation curves for CAD cells treated with DMSO (control) or 100 pM–30 μM **8**. (D) Summary of the fraction of current available at -50 mV for CAD cells treated with DMSO (control) or 100 pM–30 μM **8**. Asterisks (*) indicate statistically significant differences in fraction of current available between control and the indicated concentrations of **8** ($p < 0.05$, Student's t test). Data are from 4–7 cells per condition.

conditions. Finally, we found that **8** did not exhibit frequency (use)-dependent inhibition of Na^+ currents as currents recorded from cells treated with 10 μM **8** displayed no statistically significant differences in trend or amplitude compared with control (Figure 4). The whole-cell, patch-clamp electrophysiology for **8** mirrored aspects observed for **22** in CAD cells.⁹ For **22**, the IC_{50} value for Na^+ channel slow inactivation was 2.1 μM , and like **8**, it affected fast inactivation. However, **22** displayed frequency (use)-dependent blockage of Na^+ currents, whereas **8** did not.

We also tested the activity of **8** in rat embryonic cortical neurons. These neurons typically express Na^+ channel isoforms $\text{Na}_v1.1$, $\text{Na}_v1.2$, $\text{Na}_v1.3$, and $\text{Na}_v1.6$.²⁴ The slow inactivation,



steady-state inactivation, fast inactivation, and use-dependence of Na^+ currents in cortical neurons grown for 7–10 days in vitro (Figure 5A, D, G, and J) were examined using protocols mostly similar to those described for CAD cells with a few exceptions noted in the legend to Figure 5. A single concentration (20 μM) of **8** was chosen as it represented




Figure 3. Effects of **8** on activation and inactivation properties of Na⁺ currents in mouse CAD cells. Values for $V_{1/2}$, the voltage of half-maximal activation and steady-state fast inactivation and the slope factors (k) were derived from Boltzmann distribution fits to the individual recordings and averaged to determine the mean (\pm SEM) voltage dependence of activation and fast inactivation. The voltage protocol used to evoke current responses for each protocol is shown above the fits. Representative Boltzmann fits for activation and steady-state inactivation for CAD cells treated with 0.1% DMSO (control) and indicated concentrations of **8** are shown.




Figure 4. Lack of effect on frequency-dependent block by **8** of Na⁺ currents in mouse CAD cells. The frequency dependence of block was examined by holding cells at the hyperpolarized potential of -80 mV and evoking currents at 10 Hz by 20 -ms test pulses to -10 mV (inset middle). Representative overlaid traces are illustrated by pulses 1, 10, 20, and 30 for control (pre-drug) and in the presence of **8** ($1 \mu\text{M}$). Summary of average frequency-dependent decrease in current amplitude (\pm SEM) produced by control (pre-drug) or by the presence of **8** ($1 \mu\text{M}$) ($p > 0.05$, one-way ANOVA with Dunnett's posthoc test). Data are from 5–7 cells per condition.

almost 8-fold the IC_{50} value for slow inactivation based on CAD cell data. At this concentration, the extent of slow inactivation induced by **8** was significantly greater than neurons treated with the vehicle DMSO: 0.17 ± 0.03 ($n = 5$) versus 0.41 ± 0.05 ($n = 7$), respectively ($p > 0.05$, one-way ANOVA Figure 5B, C). Steady-state activation was also unchanged between the two conditions with the $V_{1/2}$ and k values being statistically similar (Figure 5E, F). Steady-state, fast inactivation curves of Na⁺ currents from DMSO-treated and $20 \mu\text{M}$ **8**-cortical neurons were well fitted with a single Boltzmann function ($R^2 > 0.995$ for both conditions) and are illustrated in Figure 5I. The $V_{1/2}$ value for inactivation of 0.1% DMSO-treated cells

was -53.9 ± 1.2 mV ($n = 4$), which was significantly different from the $V_{1/2}$ value of -69.6 ± 1.2 mV ($n = 5$) for **8**-treated neurons ($p < 0.05$; ANOVA with a posthoc Dunnett's test). The $20 \mu\text{M}$ concentration of **8** caused a significant hyperpolarizing shift of ~ 15.7 mV with no commensurate significant changes in slope values compared with control cells. Finally, we found that **8** did not exhibit frequency (use)-dependent inhibition of Na⁺ currents in cortical neurons (Figure 5K, L).

Compound **8**, and the other agents in this study, contained a biphenyl unit. This motif is considered a privileged substructure and has been shown to bind to many proteins, including G-protein-coupled receptors.^{25–27} Accordingly, we determined the binding of **2–11** at UNC's Psychoactive Drug Screening Program against 43 receptors. We observed appreciable binding of most compounds at $10 \mu\text{M}$ to several serotonin (e.g., 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2A}, 5-HT₆, 5-HT₇) and adrenergic (e.g., α 2A, 2B, 2C) receptors; the DAT, NET, and SERT transporters; and the sigma-1 and -2 receptors (Supplementary Table 1). The importance of these interactions on the observed anticonvulsant activities has not been determined.

CONCLUSIONS

Our previous finding that the biaryl linked unit (Figure 1) promoted Na⁺ channel slow inactivation in CAD cells⁹ led to the discovery that compounds conforming to class **B** exhibited anticonvulsant activities in proven whole animal seizure models. Structurally, **B** is exceedingly simple, readily synthesized, and soluble in water ($\geq 300 \mu\text{M}$). The anticonvulsant activity for **8** in the MES seizure model (rat, po) rivaled that of established AEDs. Compound **8** appears to exert its activity, in part, by inhibiting Na⁺ channel currents.

EXPERIMENTAL SECTION

General Methods. The general methods used in this study are identical to those previously reported.⁷ The compounds were checked by TLC, ¹H NMR and ¹³C NMR, MS, and elemental analyses. The analytical results, except for **6**, are within $\pm 0.40\%$ of the theoretical value. The NMR and analytical data confirmed that the purity of the products was $\geq 95\%$.

(Biphenyl-4-yl)methylammonium Chloride (2).²⁸ To a solution of 4-(phenyl)benzylamine (1.00 g, 5.5 mmol) in CH_2Cl_2 (50 mL) was added an HCl solution in dioxane dropwise (1.5 mL, 4 N) with stirring at room temperature (1 h). The resulting precipitate was filtered, washed with hexanes, and dried in vacuo to give **2** (1.03 g, 86%) as a white solid: $R_f = 0.00$ (hexanes/EtOAc 1/1); mp $301\text{--}303^\circ\text{C}$ (lit.²⁸ mp $308\text{--}310^\circ\text{C}$); ¹H NMR (CDCl_3 , CD_3OD) δ 4.14 (s, CH_2N), 4.62–4.78 (br s, NH_3^+), 7.32–7.41 (m, ArH), 7.42–7.48 (m, 2 ArH), 7.49 (d, $J = 8.4$ Hz, 2 ArH), 7.59 (d, $J = 8.8$ Hz, 2 ArH), 7.68 (d, $J = 8.4$ Hz, 2 ArH); ¹³C NMR (CDCl_3 , CD_3OD) δ 42.7 (CH_2N), 126.5, 127.3, 127.4, 128.5, 128.9, 131.3, 139.7, 141.9 (8 ArC); LRMS (ES^+) 184.00 [$\text{M} - \text{Cl}$]⁺ (calcd for $\text{C}_{13}\text{H}_{14}\text{N}^+$ 184.11). Anal. Calcd for $\text{C}_{13}\text{H}_{14}\text{ClN}$: C, 71.07; H, 6.42; Cl, 16.14; N, 6.38. Found: C, 70.95; H, 6.44; Cl, 16.24; N, 6.34.

(3'-Fluorobiphenyl-4-yl)methylammonium Chloride (3). To a solution of **12** (1.21 g, 6.50 mmol) in acetonitrile (65 mL) were added 3-fluorophenylboronic acid (**13**) (1.00 g, 7.15 mmol), tetrakis-(triphenylphosphine)palladium(0) (0.38 g, 0.32 mmol), and aqueous 2 N K_2CO_3 (16.2 mL). The resulting mixture was sparged with Ar with stirring (30 min) and then stirred again at 90°C under Ar (16 h). The reaction mixture was filtered and evaporated in vacuo. The resulting residue was diluted with EtOAc (50 mL) and washed with H_2O (2×50 mL) and with saturated aqueous brine solution (2×50 mL). The organic layer was dried (Na_2SO_4) and concentrated in vacuo to give the amine as a yellow oil. To a solution of the amine in ethyl acetate was added aqueous concentrated HCl (0.8 mL) with stirring at room temperature (1 h) to give a precipitate. To the resulting mixture




Figure 5. Evaluation of **8** on biophysical properties of Na^+ currents in rat embryonic cortical neurons. (A) Currents were evoked by 5 s prepulses between -100 and $+20$ mV, and then fast-inactivated channels were allowed to recover for 1000 ms at a hyperpolarized pulse to -100 mV. The fraction of channels available at 0 mV was analyzed. (B) Representative current traces from cortical neurons in the absence (control, 0.1% DMSO) or presence of $20 \mu\text{M}$ **8**. The black and red traces represent the current at -50 mV. (C) Summary of the fraction of current available at -50 mV for cortical neurons treated with DMSO (control) or $20 \mu\text{M}$ **8**. Values for $V_{1/2}$, the voltage of half-maximal activation (D–F) and steady-state fast inactivation (G–I) and the slope factors (k) were derived from Boltzmann distribution fits to the individual recordings and averaged to determine the mean (\pm SEM) voltage dependence of activation and fast inactivation. The voltage protocol used to evoke current responses for each protocol is shown above the fits. Representative Boltzmann fits for activation and steady-state inactivation for cortical neurons treated with 0.1% DMSO (control) and $20 \mu\text{M}$ **8** are shown. Fast-inactivation was significantly affected by $20 \mu\text{M}$ **8**. (J–L) Use-dependence was not affected by $20 \mu\text{M}$ **8**. Details are similar to those in legend to Figure 4. Five to seven cells were tested in these experiments.

was added H_2O , and then the aqueous layer separated. The aqueous layer was basified with aqueous 4 N NaOH and extracted with CH_2Cl_2 ($2 \times$), and the combined CH_2Cl_2 layers were dried (Na_2SO_4) and evaporated in vacuo. The resulting oil was diluted in CH_2Cl_2 , and then 4 N HCl in dioxane added. The resulting precipitate was filtered and washed with hexanes to give **3** (1.20 g, overall yield 77%) as a white solid: $R_f = 0.00$ (EtOAc/hexanes $1/1$); mp $301\text{--}304^\circ\text{C}$; ^1H NMR (CD_3OD) δ 4.18 (s, CH_2N), $7.06\text{--}7.20$ (m, ArH), $7.30\text{--}7.39$ (m, ArH), $7.43\text{--}7.48$ (m, 2 ArH), 7.58 (d, $J = 8.2$ Hz, 2 ArH), 7.71 (d, $J = 8.2$ Hz, 2 ArH); ^{13}C NMR (CD_3OD) δ 44.5 (CH_2N), 115.1 (d, $J = 20.2$ Hz), 115.9 (d, $J = 20.2$ Hz), 124.4 , 129.2 , 131.2 , 132.3 (d, $J = 8.8$ Hz), 134.6 , 142.4 (d, $J = 7.6$ Hz), 144.4 (d, $J = 7.6$ Hz), 165.2 (d, $J = 243.0$ Hz) (10 ArC); LRMS (ES^+) 201.95 [$\text{M} - \text{Cl}$] $^+$ (calcd for $\text{C}_{13}\text{H}_{13}\text{FN}^+$ 202.10). Anal. Calcd for $\text{C}_{13}\text{H}_{13}\text{ClFN}$: C, 65.69 ; H, 5.51 ; Cl, 14.91 ; F, 7.99 ; N, 5.89 . Found: C, 65.68 ; H, 5.45 ; Cl, 14.77 ; F, 7.81 ; N, 5.74 .

(4'-Fluorobiphenyl-4-yl)methylammonium Chloride (4). Employing the procedure for **3** and using **12** (5.00 g, 26.9 mmol), acetonitrile (100 mL), 4 -fluorophenylboronic acid (**14**) (3.77 g, 26.9

mmol), tetrakis(triphenylphosphine)palladium(0) (1.55 g, 1.35 mmol), and aqueous $2 \text{ N K}_2\text{CO}_3$ (53.8 mL) gave the free amine²⁹ as a yellow oil. The amine was treated with aqueous concentrated HCl (2.5 mL) and then purified to give **4** (4.99 g, overall yield 78%) as a white solid: $R_f = 0.00$ (EtOAc/hexanes $1/1$); mp $302\text{--}303^\circ\text{C}$; ^1H NMR ($\text{DMSO}-d_6$) δ 4.06 (s, CH_2N), $7.28\text{--}7.34$ (m, 2 ArH), $7.61\text{--}7.75$ (m, 6 ArH), 8.70 (s, NH_3); ^{13}C NMR ($\text{DMSO}-d_6$) δ 41.7 (CH_2N), 115.8 (d, $J = 21.3$ Hz, C_3 , C_5), 126.7 (ArC), 128.7 (d, $J = 8.0$ Hz, C_2 , C_6), 129.6 , 133.3 (2 ArC), 136.0 (d, $J = 3.7$ Hz, C_1), 139.1 (ArC), 162.0 (d, $J = 243.2$ Hz, C_4); HRMS (ESI^+) 202.1022 [$\text{M} - \text{Cl}$] $^+$ (calcd for $\text{C}_{13}\text{H}_{13}\text{FN}^+$ 202.1022). Anal. Calcd for $\text{C}_{13}\text{H}_{13}\text{ClFN}$: C, 65.69 ; H, 5.51 ; Cl, 14.91 ; F, 7.99 ; N, 5.89 . Found: C, 65.55 ; H, 5.54 ; Cl, 14.79 ; F, 7.82 ; N, 5.88 .

(3'-Chlorobiphenyl-4-yl)methylammonium Chloride (5). Employing the procedure for **3** and using **12** (2.16 g, 11.63 mmol), acetonitrile (116 mL), 3 -chlorophenylboronic acid (**15**) (4.21 g, 26.9 mmol), tetrakis(triphenylphosphine)palladium(0) (1.55 g, 1.35 mmol), and aqueous $2 \text{ N K}_2\text{CO}_3$ (53.8 mL) gave the free amine³⁰ as a yellow oil. The amine was treated with aqueous concentrated HCl

(2.5 mL) and then purified to give **5** (4.37 g, overall yield 64%) as a white solid: $R_f = 0.00$ (EtOAc/hexanes 1/1); mp 264–265 °C; ^1H NMR (DMSO- d_6) δ 4.07 (s, CH_2N), 7.43–7.76 (m, 8 ArH), 8.75 (s, NH_3Cl); ^{13}C NMR (DMSO- d_6) δ 40.5 (CH_2N), 125.4, 126.3, 126.9, 127.4, 129.7, 130.8, 133.8, 134.0, 138.5, 141.6 (10 ArC); LRMS (ES^+) 218.0 $[\text{M} - \text{Cl}]^+$ (calcd for $\text{C}_{13}\text{H}_{13}\text{ClN}^+$ 218.1). Anal. Calcd for $\text{C}_{13}\text{H}_{13}\text{Cl}_2\text{N} \cdot 0.18 \text{H}_2\text{O}$: C, 60.66; H, 5.23; Cl, 27.55; N, 5.44. Found: C, 60.30; H, 5.12; Cl, 27.16; N, 5.49.

(4'-Chlorobiphenyl-4-yl)methylammonium Chloride (6). Employing the procedure for **3** and using **12** (2.16 g, 11.63 mmol), acetonitrile (116 mL), 4-chlorophenylboronic acid (**16**) (2.00 g, 12.79 mmol), tetrakis(triphenylphosphine)palladium(0) (0.68 g, 0.58 mmol), and aqueous 2 N K_2CO_3 (29.1 mL) gave the free amine as a yellow oil. The amine was treated with aqueous concentrated HCl (0.5 mL) and then purified to give **6** (1.00 g, overall yield 100%) as a white solid: $R_f = 0.00$ (EtOAc/hexanes 1/1); mp 298–302 °C; ^1H NMR (CD_3OD) δ 4.19 (s, CH_2N), 7.42–7.46 (m, 2 ArH), 7.56–7.63 (m, 4 ArH), 7.67–7.71 (m, 2 ArH); ^{13}C NMR (CD_3OD) δ 40.5 (CH_2N), 125.1, 126.1, 126.6, 127.3, 130.4, 131.4, 136.6, 138.4 (8 ArC); HRMS (ESI^+) 218.0764 $[\text{M} - \text{Cl}]^+$ (calcd for $\text{C}_{13}\text{H}_{13}\text{ClN}^+$ 218.0736).

(2'-Trifluoromethoxybiphenyl-4-yl)methylammonium Chloride (7).³¹ Employing the procedure for **3** and using **12** (1.65 g, 8.9 mmol), acetonitrile (100 mL), 2-trifluoromethoxyphenylboronic acid (**17**) (2.00 g, 9.8 mmol), tetrakis(triphenylphosphine)palladium(0) (0.51 g, 0.44 mmol), and aqueous 2 N K_2CO_3 (17.7 mL) gave the free amine as a yellow oil. The amine was treated with aqueous concentrated HCl (2.3 mL) and then purified to give **7** (1.70 g, overall yield 57%) as a white solid: $R_f = 0.00$ (hexanes/EtOAc 1/1); mp 175–179 °C; ^1H NMR (CDCl_3 , CD_3OD) δ 4.15 (s, CH_2N), 4.23–4.40 (br s, NH_3), 7.35–7.46 (m, 5 ArH), 7.53–7.57 (br s, 3 ArH); ^{13}C NMR (CDCl_3 , CD_3OD) δ 43.0 (CH_2N), 121.4, 127.2, 128.7, 129.1, 129.9, 131.2, 132.0, 134.3, 137.9, 146.0 (10 ArC), the OCF_3 resonance was not detected and was believed to overlap with nearby peaks; LRMS (ES^+) 268.01 $[\text{M} - \text{Cl}]^+$ (calcd for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{NO}^+$ 268.09). Anal. Calcd for $\text{C}_{14}\text{H}_{13}\text{ClF}_3\text{NO}$: C, 55.37; H, 4.31; Cl, 11.67; F, 18.77; N, 4.61. Found: C, 55.48; H, 4.39; Cl, 11.48; F, 18.51; N, 4.56.

(3'-Trifluoromethoxybiphenyl-4-yl)methylammonium Chloride (8). Employing the procedure for **3** and using **12** (1.56 g, 8.4 mmol), acetonitrile (85 mL), 3-trifluoromethoxyphenylboronic acid (**18**) (2.00 g, 8.4 mmol), tetrakis(triphenylphosphine)palladium(0) (0.38 g, 0.4 mmol), and aqueous 1 N K_2CO_3 (30 mL) gave the free amine as a yellow oil. The amine was treated with aqueous concentrated HCl (0.5 mL) and then purified to give **8** (1.00 g, overall yield 70%) as a white solid: $R_f = 0.00$ (EtOAc/hexanes 1/1); mp 218–219 °C; ^1H NMR (CD_3OD) δ 4.10 (s, CH_2N), 7.38–7.40 (m, 1 ArH), 7.63–7.79 (m, 7 ArH), 8.81–8.85 (br s, NH_3Cl); ^{13}C NMR (CD_3OD) δ 51.4 (CH_2), 128.8, 129.5 (2 ArC), 129.8 (q, $J = 254.9 \text{ Hz}$, OCF_3), 135.5, 136.6, 139.4, 140.6, 143.9, 148.0, 151.6, 158.6 (8 ArC). Anal. Calcd for $\text{C}_{14}\text{H}_{13}\text{ClF}_3\text{NO}$: C, 55.37; H, 4.31; Cl, 11.67; F, 18.77; N, 4.61. Found: C, 55.36; H, 4.31; Cl, 11.55; F, 18.58; N, 4.55.

(4'-Trifluoromethoxybiphenyl-4-yl)methylammonium Chloride (9).³² Employing the procedure for **3** and using **12** (1.65 g, 8.9 mmol), acetonitrile (100 mL), 4-trifluoromethoxyphenylboronic acid (**19**) (2.00 g, 9.8 mmol), tetrakis(triphenylphosphine)palladium(0) (0.51 g, 0.44 mmol), and aqueous 2 N K_2CO_3 (17.7 mL) gave the free amine as a yellow oil. The amine was treated with aqueous concentrated HCl (2.3 mL) and then purified to give **9** (2.18 g, overall yield 74%) as a white solid: $R_f = 0.00$ (hexanes/EtOAc 1/1); mp 281–288 °C; ^1H NMR (CDCl_3 , CD_3OD) δ 4.14 (s, CH_2N), 4.24 (s, NH_3), 7.31 (d, $J = 8.8 \text{ Hz}$, 2 ArH), 7.55 (d, $J = 8.4 \text{ Hz}$, 2 ArH), 7.60–7.68 (m, 4 ArH); ^{13}C NMR (CDCl_3 , CD_3OD) δ 42.9 (CH_2N), 121.2, 127.6, 128.4, 129.4, 131.9, 138.8, 146.0, 148.9 (8 ArC), the OCF_3 resonance was not detected and was believed to overlap with nearby peaks; HRMS (ESI^+) 290.0763 $[\text{M} - \text{HCl} + \text{Na}]^+$ (calcd for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{NO}^+$ 290.0769). Anal. Calcd for $\text{C}_{14}\text{H}_{13}\text{ClF}_3\text{NO} \cdot 0.08 \text{C}_6\text{H}_{14}$: C, 55.99; H, 4.58; Cl, 11.41; F, 18.35; N, 4.51. Found: C, 56.03; H, 4.22; Cl, 11.03; F, 18.52; N, 4.50.

(3'-Methoxybiphenyl-4-yl)methylammonium Chloride (10).

Employing the procedure for **3** and using **12** (1.12 g, 6.0 mmol), acetonitrile (60 mL), 3-methoxyphenylboronic acid (**20**) (1.00 g, 6.6 mmol), tetrakis(triphenylphosphine)palladium(0) (0.35 g, 0.3 mmol), and aqueous 2 N K_2CO_3 (15.0 mL) gave the free amine as a yellow oil. The amine³⁰ was treated with aqueous concentrated HCl (1.6 mL) and then purified to give **10** (0.80 g, overall yield 54%) as a white solid: $R_f = 0.00$ (hexanes/EtOAc 1/1); mp 231–234 °C; ^1H NMR (DMSO- d_6) δ 3.83 (OCH_3), 4.05 (CH_2N), 6.95 (dd, $J = 2.2, 8.3 \text{ Hz}$, ArH), 7.20 (s, ArH), 7.25 (d, $J = 8.4 \text{ Hz}$, ArH), 7.39 (t, $J = 7.8 \text{ Hz}$, ArH), 7.50 (d, $J = 8.0 \text{ Hz}$, 2 ArH), 7.72 (d, $J = 8.0 \text{ Hz}$, 2 ArH), 8.40–8.58 (br s, NH_3); ^{13}C NMR (DMSO- d_6) δ 42.3 (CH_2N), 55.6 (OCH_3), 112.7, 113.7, 119.4, 127.3, 129.9, 130.4, 133.9, 140.5, 141.5, 160.2 (10 ArC); LRMS (ES^+) 214.09 $[\text{M} - \text{Cl}]^+$ (calcd for $\text{C}_{14}\text{H}_{16}\text{NO}^+$ 214.12). Anal. Calcd for $\text{C}_{13}\text{H}_{13}\text{Cl}_2\text{N}$: C, 67.33; H, 6.46; Cl, 14.20; N, 5.61. Found: C, 67.05; H, 6.44; Cl, 13.94; N, 5.58.

(3'-Methoxycarbonylbiphenyl-4-yl)methylammonium Chloride (11).³² Employing the procedure for **3** and using **12** (0.86 g, 4.6 mmol), acetonitrile (40 mL), 3-methoxycarbonylphenylboronic acid (**21**) (1.00 g, 5.6 mmol), tetrakis(triphenylphosphine)palladium(0) (0.27 g, 0.2 mmol), and aqueous 2 N K_2CO_3 (5 mL) gave the free amine as a yellow oil. The amine was treated with aqueous concentrated HCl (1.2 mL) and then purified to give **11** (0.71 g, overall yield 55%) as a white solid: $R_f = 0.00$ (hexanes/EtOAc 1/1); mp 215–218 °C; ^1H NMR (CD_3OD) δ 3.90 (OCH_3), 4.08 (CH_2N), 7.58–7.70 (m, 3 ArH), 7.77 (d, $J = 8.0 \text{ Hz}$, 2 ArH), 7.98 (dd, $J = 1.0, 8.0 \text{ Hz}$, 2 ArH), 8.21 (s, ArH), 8.40–8.60 (br s, NH_3); ^{13}C NMR (CD_3OD) δ 41.8 (CH_2N), 52.3 (OCH_3), 127.0, 127.1, 128.3, 129.7, 129.8, 130.4, 131.6, 133.8, 139.1, 140.0 (10 ArC), 166.2 (C(O)); LRMS (ES^+) 242.03 $[\text{M} - \text{Cl}]^+$ (calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2^+$ 242.12). Anal. Calcd for $\text{C}_{15}\text{H}_{16}\text{ClNO}_2 \cdot 0.2 \text{H}_2\text{O}$: C, 64.03; H, 5.88; Cl, 12.06; N, 4.98. Found: C, 63.65; H, 5.82; Cl, 11.84; N, 4.79.

Pharmacology. Compounds were screened under the auspices of the National Institutes of Health's ASP. Experiments were performed in male rodents (albino Carworth Farms No. 1 mice (ip), albino Sprague–Dawley rats (ip, po)). Housing, handling, and feeding were in accordance with recommendations contained in the *Guide for the Care and Use of Laboratory Animals*. Anticonvulsant activity was established using the MES test,¹⁰ 6 Hz,¹⁵ and the scMet test,¹⁶ according to previously reported methods.¹

Catecholamine A-Differentiated (CAD) Cells. CAD cells were grown at 37 °C and in 5% CO_2 (Sarstedt, Newton, NC) in Ham's F12/EMEM (GIBCO, Grand Island, NY), supplemented with 8% fetal bovine serum (Sigma, St. Louis, MO) and 1% penicillin/streptomycin (100% stocks, 10,000 U/mL penicillin G sodium and 10,000 $\mu\text{g/mL}$ streptomycin sulfate).^{5,8} Cells were passaged every 6–7 days at a 1:25 dilution.

Cortical Neurons. Rat cortical neuron cultures were prepared from cortices dissected from embryonic day 19 brains exactly as previously described.^{33,34}

Electrophysiology. Whole-cell voltage clamp recordings were performed at room temperature on CAD cells and cortical neurons using an EPC 10 Amplifier (HEKA Electronics, Lambrecht/Pfalz Germany). Electrodes were pulled from thin-walled borosilicate glass capillaries (Warner Instruments, Hamden, CT) with a P-97 electrode puller (Sutter Instrument, Novato, CA) such that final electrode resistances were 1–2 M Ω when filled with internal solutions. The internal solution for recording Na^+ currents contained (in mM) 110 CsCl, 5 MgSO_4 , 10 EGTA, 4 ATP $\text{Na}_2\text{-ATP}$, 25 HEPES (pH 7.2, 290–310 mOsm/L). The external solution contained (in mM) 100 NaCl, 10 tetraethylammonium chloride (TEA-Cl), 1 CaCl_2 , 1 CdCl_2 , 1 MgCl_2 , 10 D-glucose, 4 4-AP, 0.1 NiCl_2 , 10 HEPES (pH 7.3, 310–315 mOsm/L). Whole-cell capacitance and series resistance were compensated with the amplifier. Series resistance error was always compensated to be less than $\pm 3 \text{ mV}$. Cells were considered only when the seal resistance was less than 3 M Ω . Linear leak currents were digitally subtracted by $P/4$.

Data Acquisition and Analysis. Signals were filtered at 10 kHz and digitized at 10–20 kHz. Analysis was performed using Fitmaster and origin8.1 (OriginLab Corporation, MA, U.S.). For activation

curves, conductance (G) through Na^+ channels was calculated using the equation $G = I/(V_m - V_{\text{rev}})$, where V_{rev} is the reversal potential, V_m is the membrane potential at which the current was recorded, and I is the peak current. Activation and inactivation curves were fitted to a single-phase Boltzmann function $G/G_{\text{max}} = 1/\{1 + \exp[(V - V_{50})/k]\}$, where G is the peak conductance, G_{max} is the fitted maximal G , V_{50} is the half activation voltage, and k is the slope factor. Additional details of specific pulse protocols are described in the Results and Discussion text or figure legends.

Statistical Analyses. Differences between means were compared by either paired or unpaired, two-tailed Student's t -tests or an analysis of variance (ANOVA), when comparing multiple groups (repeated measures whenever possible). If a significant difference was determined by ANOVA, then a Dunnett's or Tukey's posthoc test was performed. Data are expressed as mean \pm SEM, with $p < 0.05$ considered as the level of significance.

■ ASSOCIATED CONTENT

Supporting Information

Receptor binding assay profile for compounds 2–11 against 43 receptors. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 919-843-8112. Fax: 919-966-0204. E-mail: hkohn@email.unc.edu.

Present Addresses

[†]Cell Dynamics Research Center, Gwangju Institute of Science and Technology, Gwangju, Korea.

[#]Center for Neuro-Medicine, Korea Institute of Science and Technology, Seoul, Korea.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work is supported by a grant from the North Carolina Biotechnology Center (Technology Enhancement Grant) administered by the University of North Carolina-Chapel Hill and awards from the Indiana Clinical and Translational Sciences Institute funded in part by a Project Development Team Grant Number (RR025761) from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award, the Indiana State Department of Health–Spinal Cord and Brain Injury Fund (A70-9-079138 to R.K.), a National Scientist Development Award from the American Heart Association (SDG5280023 to R.K.), and a Neurofibromatosis New Investigator Award from the Department of Defense Congressionally Directed Military Medical Research and Development Program (NF1000099 to R.K.). We thank the NINDS and the ASP at the National Institutes of Health with Drs. Tracy Chen and Jeffrey Jiang for kindly performing the pharmacological studies via the ASP's contract site at the University of Utah with Drs. H. Wolfe, H. S. White, and K. Wilcox. We express our appreciation to Dr. Bryan L. Roth and Mr. Jon Evans at the National Institute of Mental Health (NIMH) Psychoactive Drug Screening Project for performing in vitro receptor binding studies. This work was supported by NIMH Psychoactive Drug Screening Program, Contract No. HHSN-271-2008-00025-C (NIMH-PDSP). The NIMH PDSP is directed by Bryan Roth M.D., Ph.D. at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda, MD, U.S. The content is solely the responsibility of the authors and does not represent

the official views of the National Center for Research Resources, National Institutes of Health. H.K. has a royalty-stake position in 1.

■ ABBREVIATIONS USED

AED, antiepileptic drug; ASP, Anticonvulsant Screening Program; CAD, catecholamine A-differentiated; CF_3O , trifluoromethoxy; ED_{50} , effective dose (50%); IC_{50} , concentration at which half of the channels have transitioned to a slow-inactivated state; ip, intraperitoneally; MES, maximal electroshock seizure; NINDS, National Institute of Neurological Disorders and Stroke; PI, protective index; po, orally; scMet, scMetrazol; TD_{50} , neurological impairment (toxicity, 50%); TEA-Cl, tetraethylammonium chloride; $V_{1/2}$, voltage of half-maximal activation

■ REFERENCES

- (1) Choi, D.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant activities of *N*-benzyl-2-acetamidopropionamide derivatives. *J. Med. Chem.* **1996**, *39*, 1907–1916.
- (2) Perucca, E.; Yasothan, U.; Clincke, G.; Kirkpatrick, P. Lacosamide. *Nat. Rev. Drug Discovery* **2008**, *7*, 973–974.
- (3) Errington, A. C.; Stohr, T.; Heers, C.; Lees, G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. *Mol. Pharmacol.* **2008**, *73*, 157–169.
- (4) Sheets, P. L.; Heers, C.; Stoehr, T.; Cummins, T. R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide, lidocaine and carbamazepine. *J. Pharmacol. Exp. Ther.* **2008**, *326*, 89–99.
- (5) Wang, Y.; Park, K. D.; Salome, C.; Wilson, S. M.; Stables, J. P.; Liu, R.; Khanna, R.; Kohn, H. Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. *ACS Chem. Neurosci.* **2011**, *2*, 90–106.
- (6) Kuo, C. C.; Bean, B. P. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. *Mol. Pharmacol.* **1994**, *46*, 716–725.
- (7) Salome, C.; Salome-Grosjean, E.; Stables, J. P.; Kohn, H. Merging the structural motifs of functionalized amino acids and α -aminoamides: compounds with significant anticonvulsant activities. *J. Med. Chem.* **2010**, *53*, 3756–3771.
- (8) Wang, Y.; Wilson, S. M.; Brittain, J. M.; Ripsch, M. S.; Salome, C.; Park, K. D.; White, F. A.; Khanna, R.; Kohn, H. Merging structural motifs of functionalized amino acids and α -aminoamides results in novel anticonvulsant compounds with significant effects on slow and fast inactivation of voltage-gated sodium channels and in the treatment of neuropathic pain. *ACS Chem. Neurosci.* **2011**, *2*, 317–332.
- (9) King, A. M.; Yang, X.-F.; Wang, Y.; Dustrude, E. T.; Barbosa, C.; Due, M. R.; Piekarz, A. D.; Wilson, S. M.; White, F. A.; Salome, C.; Cummins, T. R.; Khanna, R.; Kohn, H. Identification of the benzyloxyphenyl pharmacophore: A structural unit that promotes sodium channel slow inactivation. *ACS Chem. Neurosci.* **2012**, *3*, 1037–1049.
- (10) Levy, R. H.; Mattson, R.; Meldrum, B. *Antiepileptic Drugs*, 4th ed.; Raven Press: New York, 1995.
- (11) Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scoville, B.; White, B. G. Antiepileptic drug development program. *Cleveland Clin. Q.* **1984**, *51*, 293–305.
- (12) Salome, C.; Salome-Grosjean, E.; Park, K. D.; Morieux, P.; Swendiman, R.; DeMarco, E.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant activities of (*R*)-*N*-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides. *J. Med. Chem.* **2010**, *53*, 1288–1305.
- (13) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. *Chem. Rev.* **1995**, *95*, 2457–2483.

- (14) Stables, J. P.; Kupferberg, H. G. In *Molecular and Cellular Targets for Antiepileptic Drugs*; Avanzini, G., Tanganelli, P., Avoli, M., Eds.; John Libbey: London, 1977; pp 191–198.
- (15) Barton, M. E.; Klein, B. D.; Wolff, H. H.; White, H. S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. *Epilepsy Res.* **2001**, *47*, 217–227.
- (16) Swinyard, E. A. Laboratory evaluation of antiepileptic drugs: review of laboratory methods. *Epilepsia* **1969**, *10*, 107–119.
- (17) Dunham, N. W.; Miya, T.-S. A note on a simple apparatus for detecting neurological deficit in rats and mice. *J. Am. Pharm. Assoc.* **1957**, *46*, 208–209.
- (18) White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. General Principles: Discovery and Preclinical Development of Antiepileptic Drugs. In *Antiepileptic Drugs*, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perruca, E., Eds.; Lippincott, Williams and Wilkins: Philadelphia, PA, 2002; pp 36–48.
- (19) Hodgkin, A. L.; Huxley, A. F. The dual effect of membrane potential on sodium conductance in the giant axon of *Loligo*. *J. Physiol.* **1952**, *116*, 497–506.
- (20) Rudy, B. Slow inactivation of the sodium conductance in squid giant axons. Pronase resistance. *J. Physiol.* **1978**, *283*, 1–21.
- (21) Bean, B. P. The action potential in mammalian central neurons. *Nat. Rev. Neurosci.* **2007**, *8*, 451–465.
- (22) Do, M. T. H.; Bean, B. P. Subthreshold sodium currents and pacemaking of subthalamic neurons: Modulation by slow inactivation. *Neuron* **2003**, *39*, 109–120.
- (23) Vilin, Y. Y.; Ruben, P. C. Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. *Cell Biochem. Biophys.* **2001**, *35*, 171–190.
- (24) Goldin, A. L. Resurgence of sodium channel research. *Annu. Rev. Physiol.* **2001**, *63*, 871–894.
- (25) Horton, D. A.; Bourne, G. T.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. *Chem. Rev.* **2003**, *103*, 893–930.
- (26) Bleicher, K. H.; Green, L. G.; Martin, R. E.; Rogers-Evans, M. Ligand identification for G-protein-coupled receptors: a lead generation perspective. *Curr. Opin. Chem. Biol.* **2004**, *8*, 287–296.
- (27) Corbett, D. F.; Heightman, T. D.; Moss, S. F.; Bromidge, S. M.; Coggon, S. A.; Longley, M. J.; Roa, A. M.; Williams, J. A.; Thomas, D. R. Discovery of a potent and selective 5-HT_{2A} receptor antagonist by high-throughput chemistry. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4014–4018.
- (28) Goldschmidt, St.; Modderman, P. Biphenyl derivatives II. Basic 4-biphenyl compounds. *Rec. Trav. Chim. Pays-Bas Belg.* **1950**, *69*, 1109–1117.
- (29) Galiano, S.; Ceras, J.; Cirauqui, N.; Perez, S.; Juanenea, L.; Rivera, G.; Aldana, I.; Monge, A. Novel series of substituted biphenylmethyl urea derivatives as MCH-R1 antagonists for the treatment of obesity. *Bioorg. Med. Chem.* **2007**, *15*, 3896–3911.
- (30) Bhuniya, D.; Umrani, D.; Dave, B.; Salunke, D.; Kukreja, G.; Gundu, J.; Naykodi, M.; Shaikh, N. S.; Shitole, P.; Kurhade, S. Discovery of a potent and selective small molecule hGPR91 antagonist. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 3596–3602.
- (31) Guo, Z.; Orth, P.; Zhu, Z.; Mazzola, R. D.; Chan, T. Y.; Vaccaro, H. A.; McKittrick, B.; Kozlowski, J. A.; Lavey, B. J.; Zhou, G.; Paliwal, S.; Wong, S.; Shih, N.; Ting, P. C.; Rosner, K. E.; Shipps, G. W., Jr.; Siddiqui, M. A.; Belanger, D. B.; Dai, C.; Li, D.; Girijavallabhan, V. M.; Popovici-Muller, J.; Yu, W.; Zhao, L. Preparation of tartaric acid functional compounds for the treatment of inflammatory disorders. PCT Int. Appl. (2005), WO 2005121130 A2 20051222.
- (32) Okada, I.; Takizawa, E.; Kikutake, K.; Fukuchi, T. Preparation of pyrazolecarboxamide derivatives as pest control agents, fungicides, and acaricides. PCT Int. Appl. (2002), WO 2002083647 A1 20021024.
- (33) Brittain, J. M.; Piekarz, A. D.; Wang, Y.; Kondo, T.; Cummins, T. R.; Khanna, R. An atypical role for collapsing response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated Ca²⁺ channels. *J. Biol. Chem.* **2009**, *284*, 31375–31390.
- (34) Brittain, J. M.; Wang, Y.; Eruvwetere, O.; Khanna, R. Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. *FEBS Lett.* **2012**, *586*, 3813–3818.